trending Market Intelligence /marketintelligence/en/news-insights/trending/-quY8ZHmc2LATISMOCuUKw2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Anthem to end prior authorization policy for opioid use disorder treatment

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates

Blog

COVID-19 Impact & Recovery: Investment Banking


Anthem to end prior authorization policy for opioid use disorder treatment

Anthem Inc., including Empire BlueCross BlueShield, will no longer require prior authorization for medication-assisted treatment for opioid use disorder, New York Attorney General Eric Schneiderman said in a news release.

The policy change will apply to Anthem members in the U.S.

In addition, Empire BlueCross BlueShield will also introduce an initiative to expand access to medication-assisted treatment for members in its New York service area.

Anthem required prior authorization for medication-assisted treatment requests, even though it did not require prior authorization for powerful opioids when prescribed for pain. With the requirement, Empire BlueCross BlueShield denied nearly 8% of the overall requests for coverage of medication-assisted treatment in 2015 and the first half of 2016. The agreement with Anthem resolves Schneiderman's investigation of prior authorization practices and network adequacy for medication-assisted treatment.

In October 2016, Cigna Corp. also agreed to end pre-authorization requirement for opioid use disorder treatment.